Investing
Payments to Acquire in Process Research and Development
Over 2 years (FY 2021 to FY 2024), Payments to Acquire in Process Research and Development shows a downward trend with a -100.0% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
First reportedQ1 2015
Last reportedQ1 2026Apr 29, 2026
Metric ID:
investing_payments_to_acquire_in_process_research_and_de_b0355bHistorical Data
14 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $18M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $35M |
| QoQ Change | — | — | -100.0% | — | — | — | — | — | — | — | — | — | — | — |
Range$0 – $35M
Payments to Acquire in Process Research and Development at Other Companies
Frequently Asked Questions
- What is Biogen's payments to acquire in process research and development?
- Biogen (BIIB) reported payments to acquire in process research and development of $35M in Q1 2026.
- What is the long-term trend for Biogen's payments to acquire in process research and development?
- Over 2 years (2021 to 2024), Biogen's payments to acquire in process research and development has grown at a -100.0% compound annual growth rate (CAGR), from $18M to $0.